<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 14 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:inherit;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
h1
	{mso-style-link:"Heading 1 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:24.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:13.5pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-button, li.ui-button, div.ui-button
	{mso-style-name:ui-button;
	margin-right:1.2pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner, li.ui-spinner, div.ui-spinner
	{mso-style-name:ui-spinner;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner-input, li.ui-spinner-input, div.ui-spinner-input
	{mso-style-name:ui-spinner-input;
	margin-top:2.4pt;
	margin-right:16.5pt;
	margin-bottom:2.4pt;
	margin-left:4.8pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-hidden-accessible, li.ui-helper-hidden-accessible, div.ui-helper-hidden-accessible
	{mso-style-name:ui-helper-hidden-accessible;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-buttonset, li.ui-buttonset, div.ui-buttonset
	{mso-style-name:ui-buttonset;
	margin-right:5.25pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker, li.ui-datepicker, div.ui-datepicker
	{mso-style-name:ui-datepicker;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-datepicker-row-break, li.ui-datepicker-row-break, div.ui-datepicker-row-break
	{mso-style-name:ui-datepicker-row-break;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-rtl, li.ui-datepicker-rtl, div.ui-datepicker-rtl
	{mso-style-name:ui-datepicker-rtl;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	direction:rtl;
	unicode-bidi:embed;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu, li.ui-menu, div.ui-menu
	{mso-style-name:ui-menu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar, li.ui-progressbar, div.ui-progressbar
	{mso-style-name:ui-progressbar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-handle, li.ui-resizable-handle, div.ui-resizable-handle
	{mso-style-name:ui-resizable-handle;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-n, li.ui-resizable-n, div.ui-resizable-n
	{mso-style-name:ui-resizable-n;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-s, li.ui-resizable-s, div.ui-resizable-s
	{mso-style-name:ui-resizable-s;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-e, li.ui-resizable-e, div.ui-resizable-e
	{mso-style-name:ui-resizable-e;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-w, li.ui-resizable-w, div.ui-resizable-w
	{mso-style-name:ui-resizable-w;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-se, li.ui-resizable-se, div.ui-resizable-se
	{mso-style-name:ui-resizable-se;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-sw, li.ui-resizable-sw, div.ui-resizable-sw
	{mso-style-name:ui-resizable-sw;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-nw, li.ui-resizable-nw, div.ui-resizable-nw
	{mso-style-name:ui-resizable-nw;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-ne, li.ui-resizable-ne, div.ui-resizable-ne
	{mso-style-name:ui-resizable-ne;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectable-helper, li.ui-selectable-helper, div.ui-selectable-helper
	{mso-style-name:ui-selectable-helper;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-menu, li.ui-selectmenu-menu, div.ui-selectmenu-menu
	{mso-style-name:ui-selectmenu-menu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-selectmenu-open, li.ui-selectmenu-open, div.ui-selectmenu-open
	{mso-style-name:ui-selectmenu-open;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-button, li.ui-selectmenu-button, div.ui-selectmenu-button
	{mso-style-name:ui-selectmenu-button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider, li.ui-slider, div.ui-slider
	{mso-style-name:ui-slider;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-horizontal, li.ui-slider-horizontal, div.ui-slider-horizontal
	{mso-style-name:ui-slider-horizontal;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-vertical, li.ui-slider-vertical, div.ui-slider-vertical
	{mso-style-name:ui-slider-vertical;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner-button, li.ui-spinner-button, div.ui-spinner-button
	{mso-style-name:ui-spinner-button;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:6.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tooltip, li.ui-tooltip, div.ui-tooltip
	{mso-style-name:ui-tooltip;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-default, li.ui-state-default, div.ui-state-default
	{mso-style-name:ui-state-default;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-focus, li.ui-state-focus, div.ui-state-focus
	{mso-style-name:ui-state-focus;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover, li.ui-state-hover, div.ui-state-hover
	{mso-style-name:ui-state-hover;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active, li.ui-state-active, div.ui-state-active
	{mso-style-name:ui-state-active;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-highlight, li.ui-state-highlight, div.ui-state-highlight
	{mso-style-name:ui-state-highlight;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-error, li.ui-state-error, div.ui-state-error
	{mso-style-name:ui-state-error;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text, li.ui-state-error-text, div.ui-state-error-text
	{mso-style-name:ui-state-error-text;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-priority-primary, li.ui-priority-primary, div.ui-priority-primary
	{mso-style-name:ui-priority-primary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-secondary, li.ui-priority-secondary, div.ui-priority-secondary
	{mso-style-name:ui-priority-secondary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled, li.ui-state-disabled, div.ui-state-disabled
	{mso-style-name:ui-state-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-hidden, li.ui-helper-hidden, div.ui-helper-hidden
	{mso-style-name:ui-helper-hidden;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-helper-reset, li.ui-helper-reset, div.ui-helper-reset
	{mso-style-name:ui-helper-reset;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-zfix, li.ui-helper-zfix, div.ui-helper-zfix
	{mso-style-name:ui-helper-zfix;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget-overlay, li.ui-widget-overlay, div.ui-widget-overlay
	{mso-style-name:ui-widget-overlay;
	margin-right:0in;
	margin-left:0in;
	background:#AAAAAA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-clearfix, li.ui-helper-clearfix, div.ui-helper-clearfix
	{mso-style-name:ui-helper-clearfix;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon, li.ui-icon, div.ui-icon
	{mso-style-name:ui-icon;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget-content, li.ui-widget-content, div.ui-widget-content
	{mso-style-name:ui-widget-content;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#222222;}
p.ui-widget-header, li.ui-widget-header, div.ui-widget-header
	{mso-style-name:ui-widget-header;
	margin-right:0in;
	margin-left:0in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#222222;
	font-weight:bold;}
p.ui-widget-shadow, li.ui-widget-shadow, div.ui-widget-shadow
	{mso-style-name:ui-widget-shadow;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:-6.0pt;
	margin-bottom:.0001pt;
	background:#AAAAAA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget, li.ui-widget, div.ui-widget
	{mso-style-name:ui-widget;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.ui-tabs, li.ui-tabs, div.ui-tabs
	{mso-style-name:ui-tabs;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog, li.ui-dialog, div.ui-dialog
	{mso-style-name:ui-dialog;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-titlebar, li.ui-dialog-titlebar, div.ui-dialog-titlebar
	{mso-style-name:ui-dialog-titlebar;
	margin-right:0in;
	margin-left:0in;
	background:#3E72A6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.ui-ncbiautocomplete-actions, li.ui-ncbiautocomplete-actions, div.ui-ncbiautocomplete-actions
	{mso-style-name:ui-ncbiautocomplete-actions;
	margin-top:.75pt;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:#CECECE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref, li.ui-ncbiautocomplete-link-pref, div.ui-ncbiautocomplete-link-pref
	{mso-style-name:ui-ncbiautocomplete-link-pref;
	margin-right:0in;
	margin-left:0in;
	text-indent:-945.65pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton, li.ui-ncbibutton, div.ui-ncbibutton
	{mso-style-name:ui-ncbibutton;
	margin-right:1.2pt;
	margin-left:0in;
	text-align:center;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:inherit;}
p.ui-button-icon-only, li.ui-button-icon-only, div.ui-button-icon-only
	{mso-style-name:ui-button-icon-only;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icons-only, li.ui-button-icons-only, div.ui-button-icons-only
	{mso-style-name:ui-button-icons-only;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-outer-div, li.ui-ncbigrid-outer-div, div.ui-ncbigrid-outer-div
	{mso-style-name:ui-ncbigrid-outer-div;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:33.6pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-inner-div, li.ui-ncbigrid-inner-div, div.ui-ncbigrid-inner-div
	{mso-style-name:ui-ncbigrid-inner-div;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-filter-toolbar, li.ui-ncbigrid-filter-toolbar, div.ui-ncbigrid-filter-toolbar
	{mso-style-name:ui-ncbigrid-filter-toolbar;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	line-height:20.25pt;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-toolbar, li.ui-ncbigrid-paged-toolbar, div.ui-ncbigrid-paged-toolbar
	{mso-style-name:ui-ncbigrid-paged-toolbar;
	margin-right:0in;
	margin-left:0in;
	line-height:19.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-checkbox-toolbar, li.ui-ncbigrid-checkbox-toolbar, div.ui-ncbigrid-checkbox-toolbar
	{mso-style-name:ui-ncbigrid-checkbox-toolbar;
	margin-right:0in;
	margin-left:0in;
	line-height:21.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-countitems, li.ui-ncbigrid-paged-countitems, div.ui-ncbigrid-paged-countitems
	{mso-style-name:ui-ncbigrid-paged-countitems;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-pagecontrol, li.ui-ncbigrid-paged-pagecontrol, div.ui-ncbigrid-paged-pagecontrol
	{mso-style-name:ui-ncbigrid-paged-pagecontrol;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-toolbar-bottom, li.ui-ncbigrid-paged-toolbar-bottom, div.ui-ncbigrid-paged-toolbar-bottom
	{mso-style-name:ui-ncbigrid-paged-toolbar-bottom;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-question, li.ui-ncbigrid-select-question, div.ui-ncbigrid-select-question
	{mso-style-name:ui-ncbigrid-select-question;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbigrid-select-question-footer, li.ui-ncbigrid-select-question-footer, div.ui-ncbigrid-select-question-footer
	{mso-style-name:ui-ncbigrid-select-question-footer;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenu, li.ui-ncbibasicmenu, div.ui-ncbibasicmenu
	{mso-style-name:ui-ncbibasicmenu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenuli, li.ui-ncbibasicmenuli, div.ui-ncbibasicmenuli
	{mso-style-name:ui-ncbibasicmenu>li;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.orientationhortli, li.orientationhortli, div.orientationhortli
	{mso-style-name:orientation_hort>li;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbimenu, li.jig-ncbimenu, div.jig-ncbimenu
	{mso-style-name:jig-ncbimenu;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbimenuli, li.jig-ncbimenuli, div.jig-ncbimenuli
	{mso-style-name:jig-ncbimenu>li;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbipopper-wrapper, li.ui-ncbipopper-wrapper, div.ui-ncbipopper-wrapper
	{mso-style-name:ui-ncbipopper-wrapper;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbipopper-basic, li.ui-ncbipopper-basic, div.ui-ncbipopper-basic
	{mso-style-name:ui-ncbipopper-basic;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#303030;}
p.brieflinkpopdesc, li.brieflinkpopdesc, div.brieflinkpopdesc
	{mso-style-name:brieflinkpopdesc;
	margin-top:4.8pt;
	margin-right:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbitoggler-slave, li.ui-ncbitoggler-slave, div.ui-ncbitoggler-slave
	{mso-style-name:ui-ncbitoggler-slave;
	margin-top:2.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbitoggler-slave-open, li.ui-ncbitoggler-slave-open, div.ui-ncbitoggler-slave-open
	{mso-style-name:ui-ncbitoggler-slave-open;
	margin-top:2.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbilinksmenu, li.ui-ncbilinksmenu, div.ui-ncbilinksmenu
	{mso-style-name:ui-ncbilinksmenu;
	margin-right:0in;
	margin-left:0in;
	background:#FCFCFC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#999999;
	font-weight:bold;}
p.ui-ncbilinksmenu-loadingmessage, li.ui-ncbilinksmenu-loadingmessage, div.ui-ncbilinksmenu-loadingmessage
	{mso-style-name:ui-ncbilinksmenu-loadingmessage;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiclearbutton-wrap, li.ui-ncbiclearbutton-wrap, div.ui-ncbiclearbutton-wrap
	{mso-style-name:ui-ncbiclearbutton-wrap;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiexpander, li.ui-ncbiexpander, div.ui-ncbiexpander
	{mso-style-name:ui-ncbiexpander;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiexpander-simple, li.ui-ncbiexpander-simple, div.ui-ncbiexpander-simple
	{mso-style-name:ui-ncbiexpander-simple;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-expander-arrow-bar, li.ui-expander-arrow-bar, div.ui-expander-arrow-bar
	{mso-style-name:ui-expander-arrow-bar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-expander-controllink, li.ui-expander-controllink, div.ui-expander-controllink
	{mso-style-name:ui-expander-controllink;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbiinpagenav-goto-container, li.jig-ncbiinpagenav-goto-container, div.jig-ncbiinpagenav-goto-container
	{mso-style-name:jig-ncbiinpagenav-goto-container;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch, li.ui-ncbisetswitch, div.ui-ncbisetswitch
	{mso-style-name:ui-ncbisetswitch;
	margin-right:0in;
	margin-left:0in;
	background:#F6F6F6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;}
p.ui-ncbisetswitch-hasstar, li.ui-ncbisetswitch-hasstar, div.ui-ncbisetswitch-hasstar
	{mso-style-name:ui-ncbisetswitch-hasstar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fg-button-icon-left, li.fg-button-icon-left, div.fg-button-icon-left
	{mso-style-name:fg-button-icon-left;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbihistogram, li.jig-ncbihistogram, div.jig-ncbihistogram
	{mso-style-name:jig-ncbihistogram;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram, li.ui-ncbihistogram, div.ui-ncbihistogram
	{mso-style-name:ui-ncbihistogram;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-display-area, li.ui-ncbihistogram-display-area, div.ui-ncbihistogram-display-area
	{mso-style-name:ui-ncbihistogram-display-area;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-display-areaollih3, li.ui-ncbihistogram-display-areaollih3, div.ui-ncbihistogram-display-areaollih3
	{mso-style-name:ui-ncbihistogram-display-area>ol>li>h3;
	margin:0in;
	margin-bottom:.0001pt;
	text-indent:366.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-controls, li.ui-ncbihistogram-controls, div.ui-ncbihistogram-controls
	{mso-style-name:ui-ncbihistogram-controls;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-left, li.ui-ncbihistogram-left, div.ui-ncbihistogram-left
	{mso-style-name:ui-ncbihistogram-left;
	margin-right:0in;
	margin-left:2.25pt;
	text-align:center;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-right, li.ui-ncbihistogram-right, div.ui-ncbihistogram-right
	{mso-style-name:ui-ncbihistogram-right;
	margin-right:2.25pt;
	margin-left:0in;
	text-align:center;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-left-disabled, li.ui-ncbihistogram-left-disabled, div.ui-ncbihistogram-left-disabled
	{mso-style-name:ui-ncbihistogram-left-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#DDDDDD;}
p.ui-ncbihistogram-right-disabled, li.ui-ncbihistogram-right-disabled, div.ui-ncbihistogram-right-disabled
	{mso-style-name:ui-ncbihistogram-right-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#DDDDDD;}
p.ui-ncbihistogram-text, li.ui-ncbihistogram-text, div.ui-ncbihistogram-text
	{mso-style-name:ui-ncbihistogram-text;
	margin-top:0in;
	margin-right:12.75pt;
	margin-bottom:0in;
	margin-left:12.75pt;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:21.8pt;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-tooltip, li.ui-ncbihistogram-tooltip, div.ui-ncbihistogram-tooltip
	{mso-style-name:ui-ncbihistogram-tooltip;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	display:none;}
p.ncbiactivevalidationmsg, li.ncbiactivevalidationmsg, div.ncbiactivevalidationmsg
	{mso-style-name:ncbiactivevalidation_msg;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ncbiactivevalidationmsgchecking, li.ncbiactivevalidationmsgchecking, div.ncbiactivevalidationmsgchecking
	{mso-style-name:ncbiactivevalidation_msg_checking;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#FF9900;}
p.ncbiactivevalidationmsgvalid, li.ncbiactivevalidationmsgvalid, div.ncbiactivevalidationmsgvalid
	{mso-style-name:ncbiactivevalidation_msg_valid;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:green;}
p.ncbiactivevalidationmsgerror, li.ncbiactivevalidationmsgerror, div.ncbiactivevalidationmsgerror
	{mso-style-name:ncbiactivevalidation_msg_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.ncbiactivevalidationmsginfo, li.ncbiactivevalidationmsginfo, div.ncbiactivevalidationmsginfo
	{mso-style-name:ncbiactivevalidation_msg_info;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:blue;}
p.ncbiactivevalidationelerror, li.ncbiactivevalidationelerror, div.ncbiactivevalidationelerror
	{mso-style-name:ncbiactivevalidation_el_error;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.social-buttons, li.social-buttons, div.social-buttons
	{mso-style-name:social-buttons;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.inlinelist, li.inlinelist, div.inlinelist
	{mso-style-name:inline_list;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.inline, li.inline, div.inline
	{mso-style-name:inline;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fig, li.fig, div.fig
	{mso-style-name:fig;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.table, li.table, div.table
	{mso-style-name:table;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pmc-wm, li.pmc-wm, div.pmc-wm
	{mso-style-name:pmc-wm;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.attic, li.attic, div.attic
	{mso-style-name:attic;
	margin-right:0in;
	margin-left:0in;
	background:#336699;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.basement, li.basement, div.basement
	{mso-style-name:basement;
	margin-right:0in;
	margin-left:0in;
	background:#336699;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-breadcrumbs, li.page-breadcrumbs, div.page-breadcrumbs
	{mso-style-name:page-breadcrumbs;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.first-line-outdent, li.first-line-outdent, div.first-line-outdent
	{mso-style-name:first-line-outdent;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vatop, li.vatop, div.vatop
	{mso-style-name:va_top;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vamiddle, li.vamiddle, div.vamiddle
	{mso-style-name:va_middle;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.qtrhythm, li.qtrhythm, div.qtrhythm
	{mso-style-name:qt_rhythm;
	margin-top:4.15pt;
	margin-right:0in;
	margin-bottom:4.15pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notopmargin, li.notopmargin, div.notopmargin
	{mso-style-name:no_top_margin;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nobottommargin, li.nobottommargin, div.nobottommargin
	{mso-style-name:no_bottom_margin;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tscanvas, li.tscanvas, div.tscanvas
	{mso-style-name:ts_canvas;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tsbar, li.tsbar, div.tsbar
	{mso-style-name:ts_bar;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#DCF0F4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-reuse, li.fm-reuse, div.fm-reuse
	{mso-style-name:fm-reuse;
	margin-right:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-subtitle, li.fm-subtitle, div.fm-subtitle
	{mso-style-name:fm-subtitle;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:15.0pt;
	font-family:"Times New Roman","serif";}
p.fm-copyright-license, li.fm-copyright-license, div.fm-copyright-license
	{mso-style-name:fm-copyright-license;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-citation-from, li.fm-citation-from, div.fm-citation-from
	{mso-style-name:fm-citation-from;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ft-thumb-box, li.ft-thumb-box, div.ft-thumb-box
	{mso-style-name:ft-thumb-box;
	margin:8.3pt;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ft-thumb-current, li.ft-thumb-current, div.ft-thumb-current
	{mso-style-name:ft-thumb-current;
	margin-right:0in;
	margin-left:0in;
	background:#D0DCE8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tab, li.tab, div.tab
	{mso-style-name:tab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.arrowtab, li.arrowtab, div.arrowtab
	{mso-style-name:arrowtab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.blanktab, li.blanktab, div.blanktab
	{mso-style-name:blanktab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.thistab, li.thistab, div.thistab
	{mso-style-name:thistab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;}
p.doi, li.doi, div.doi
	{mso-style-name:doi;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.msg-error, li.msg-error, div.msg-error
	{mso-style-name:msg-error;
	margin-right:0in;
	margin-left:0in;
	background:yellow;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.msg-warning, li.msg-warning, div.msg-warning
	{mso-style-name:msg-warning;
	margin-right:0in;
	margin-left:0in;
	background:yellow;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:brown;}
p.nihms-highlight, li.nihms-highlight, div.nihms-highlight
	{mso-style-name:nihms-highlight;
	margin-top:0in;
	margin-right:2.4pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:center;
	background:yellow;
	font-size:10.5pt;
	font-family:"Times New Roman","serif";
	color:#990000;}
p.head, li.head, div.head
	{mso-style-name:head;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sub-head, li.sub-head, div.sub-head
	{mso-style-name:sub-head;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.headless, li.headless, div.headless
	{mso-style-name:headless;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sub-navigation, li.sub-navigation, div.sub-navigation
	{mso-style-name:sub-navigation;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sec, li.sec, div.sec
	{mso-style-name:sec;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content-branding, li.content-branding, div.content-branding
	{mso-style-name:content-branding;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-generic-logo-background, li.banner-generic-logo-background, div.banner-generic-logo-background
	{mso-style-name:banner-generic-logo-background;
	margin-right:0in;
	margin-left:0in;
	background:silver;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.banner-journal-name, li.banner-journal-name, div.banner-journal-name
	{mso-style-name:banner-journal-name;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:20.5pt;
	font-family:"Calibri","sans-serif";
	font-variant:small-caps;
	letter-spacing:.3pt;}
p.banner-journal-publisher-over-image, li.banner-journal-publisher-over-image, div.banner-journal-publisher-over-image
	{mso-style-name:banner-journal-publisher-over-image;
	margin-right:7.5pt;
	margin-left:63.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-publisher-name, li.banner-publisher-name, div.banner-publisher-name
	{mso-style-name:banner-publisher-name;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:9.5pt;
	font-family:"Calibri","sans-serif";
	color:#AA1111;
	font-weight:bold;}
p.bl-w-jtitle-over, li.bl-w-jtitle-over, div.bl-w-jtitle-over
	{mso-style-name:bl-w-jtitle-over;
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	font-variant:small-caps;}
p.bl-w-jtitle-over-ph, li.bl-w-jtitle-over-ph, div.bl-w-jtitle-over-ph
	{mso-style-name:bl-w-jtitle-over-ph;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-w-jtitle-over-ph-content, li.bl-w-jtitle-over-ph-content, div.bl-w-jtitle-over-ph-content
	{mso-style-name:bl-w-jtitle-over-ph-content;
	margin-top:3.0pt;
	margin-right:6.0pt;
	margin-bottom:3.0pt;
	margin-left:78.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-journal-publisher-over-image-elsevierwt, li.banner-journal-publisher-over-image-elsevierwt, div.banner-journal-publisher-over-image-elsevierwt
	{mso-style-name:banner-journal-publisher-over-image-elsevierwt;
	margin-top:0in;
	margin-right:120.0pt;
	margin-bottom:0in;
	margin-left:15.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.elsevierwt-sponsored-label, li.elsevierwt-sponsored-label, div.elsevierwt-sponsored-label
	{mso-style-name:elsevierwt-sponsored-label;
	margin-right:0in;
	margin-left:-9.0pt;
	line-height:13.5pt;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	font-variant:small-caps;
	letter-spacing:.9pt;
	font-style:italic;}
p.bl-jtitle-sageopen, li.bl-jtitle-sageopen, div.bl-jtitle-sageopen
	{mso-style-name:bl-jtitle-sageopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#0055A5;}
p.bl-jtitle-iospressopenlib, li.bl-jtitle-iospressopenlib, div.bl-jtitle-iospressopenlib
	{mso-style-name:bl-jtitle-iospressopenlib;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-apasd, li.bl-jtitle-apasd, div.bl-jtitle-apasd
	{mso-style-name:bl-jtitle-apasd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#1E73B3;}
p.bl-jtitle-springeropen, li.bl-jtitle-springeropen, div.bl-jtitle-springeropen
	{mso-style-name:bl-jtitle-springeropen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#F0F0F0;}
p.bl-jtitle-sfesd, li.bl-jtitle-sfesd, div.bl-jtitle-sfesd
	{mso-style-name:bl-jtitle-sfesd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-acssd, li.bl-jtitle-acssd, div.bl-jtitle-acssd
	{mso-style-name:bl-jtitle-acssd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#1E73B3;}
p.bl-jtitle-esesd, li.bl-jtitle-esesd, div.bl-jtitle-esesd
	{mso-style-name:bl-jtitle-esesd;
	margin-right:0in;
	margin-left:0in;
	line-height:33.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-jtitle-srfsd, li.bl-jtitle-srfsd, div.bl-jtitle-srfsd
	{mso-style-name:bl-jtitle-srfsd;
	margin-right:0in;
	margin-left:0in;
	line-height:33.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-jtitle-tea, li.bl-jtitle-tea, div.bl-jtitle-tea
	{mso-style-name:bl-jtitle-tea;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#861316;}
p.bl-jtitle-rcpsychsd, li.bl-jtitle-rcpsychsd, div.bl-jtitle-rcpsychsd
	{mso-style-name:bl-jtitle-rcpsychsd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#44448A;}
p.bl-jtitle-npgopen, li.bl-jtitle-npgopen, div.bl-jtitle-npgopen
	{mso-style-name:bl-jtitle-npgopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-maneyopen, li.bl-jtitle-maneyopen, div.bl-jtitle-maneyopen
	{mso-style-name:bl-jtitle-maneyopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-bmjgroup, li.bl-jtitle-bmjgroup, div.bl-jtitle-bmjgroup
	{mso-style-name:bl-jtitle-bmjgroup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#003366;}
p.bl-jtitle-clpt, li.bl-jtitle-clpt, div.bl-jtitle-clpt
	{mso-style-name:bl-jtitle-clpt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-nihpa-wiley, li.bl-jtitle-nihpa-wiley, div.bl-jtitle-nihpa-wiley
	{mso-style-name:bl-jtitle-nihpa-wiley;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-rsmsd, li.bl-jtitle-rsmsd, div.bl-jtitle-rsmsd
	{mso-style-name:bl-jtitle-rsmsd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-hogrefesd, li.bl-jtitle-hogrefesd, div.bl-jtitle-hogrefesd
	{mso-style-name:bl-jtitle-hogrefesd;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#025490;}
p.mp-outer, li.mp-outer, div.mp-outer
	{mso-style-name:mp-outer;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mp-outerdiv, li.mp-outerdiv, div.mp-outerdiv
	{mso-style-name:mp-outer>div;
	margin:1.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-highlight1, li.toc-highlight1, div.toc-highlight1
	{mso-style-name:toc-highlight1;
	margin-right:0in;
	margin-left:0in;
	background:#FFFFD0;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-highlight2, li.toc-highlight2, div.toc-highlight2
	{mso-style-name:toc-highlight2;
	margin-right:0in;
	margin-left:0in;
	background:#ACE4FF;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-hl-inaugural, li.toc-hl-inaugural, div.toc-hl-inaugural
	{mso-style-name:toc-hl-inaugural;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#E64A00;}
p.courtesy-note, li.courtesy-note, div.courtesy-note
	{mso-style-name:courtesy-note;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.Footer1, li.Footer1, div.Footer1
	{mso-style-name:Footer1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.suppmat, li.suppmat, div.suppmat
	{mso-style-name:suppmat;
	margin-top:8.3pt;
	margin-right:0in;
	margin-bottom:8.3pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.aligncenter, li.aligncenter, div.aligncenter
	{mso-style-name:align_center;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mul-switcher, li.mul-switcher, div.mul-switcher
	{mso-style-name:mul-switcher;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.Strong1, li.Strong1, div.Strong1
	{mso-style-name:Strong1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.red, li.red, div.red
	{mso-style-name:red;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.navigator, li.navigator, div.navigator
	{mso-style-name:navigator;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F6F6F6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.summary, li.summary, div.summary
	{mso-style-name:summary;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.head1a, li.head1a, div.head1a
	{mso-style-name:head1a;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-header, li.navigator-header, div.navigator-header
	{mso-style-name:navigator-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-footer, li.navigator-footer, div.navigator-footer
	{mso-style-name:navigator-footer;
	margin-top:7.5pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-bar, li.navigator-bar, div.navigator-bar
	{mso-style-name:navigator-bar;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-page, li.navigator-page, div.navigator-page
	{mso-style-name:navigator-page;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-bar-table, li.navigator-bar-table, div.navigator-bar-table
	{mso-style-name:navigator-bar-table;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.section-with-images-on-the-same-page, li.section-with-images-on-the-same-page, div.section-with-images-on-the-same-page
	{mso-style-name:section-with-images-on-the-same-page;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.main-archive-list-of-volumes, li.main-archive-list-of-volumes, div.main-archive-list-of-volumes
	{mso-style-name:main-archive-list-of-volumes;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.archive-header, li.archive-header, div.archive-header
	{mso-style-name:archive-header;
	margin-right:0in;
	margin-bottom:7.5pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.journal-block-title, li.journal-block-title, div.journal-block-title
	{mso-style-name:journal-block-title;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#CCD8E4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	font-weight:bold;}
p.vol-year-cell, li.vol-year-cell, div.vol-year-cell
	{mso-style-name:vol-year-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#CCD8E4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	font-weight:bold;}
p.issue-block, li.issue-block, div.issue-block
	{mso-style-name:issue-block;
	margin-right:0in;
	margin-left:0in;
	background:#8CACCC;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-dark-row, li.iss-dark-row, div.iss-dark-row
	{mso-style-name:iss-dark-row;
	margin-right:0in;
	margin-left:0in;
	background:#EFF1F3;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-light-row, li.iss-light-row, div.iss-light-row
	{mso-style-name:iss-light-row;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-cell, li.iss-cell, div.iss-cell
	{mso-style-name:iss-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vol-cell, li.vol-cell, div.vol-cell
	{mso-style-name:vol-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.arc-issue, li.arc-issue, div.arc-issue
	{mso-style-name:arc-issue;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#0055AA;}
p.large-thumb-canvas, li.large-thumb-canvas, div.large-thumb-canvas
	{mso-style-name:large-thumb-canvas;
	margin:8.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;
	display:none;}
p.co, li.co, div.co
	{mso-style-name:co;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.co-default, li.co-default, div.co-default
	{mso-style-name:co-default;
	margin:8.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;}
p.large-thumb-canvas-1, li.large-thumb-canvas-1, div.large-thumb-canvas-1
	{mso-style-name:large-thumb-canvas-1;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.co-inner, li.co-inner, div.co-inner
	{mso-style-name:co-inner;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.in-progress, li.in-progress, div.in-progress
	{mso-style-name:in-progress;
	margin:1.5pt;
	background:#444444;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.large-thumb, li.large-thumb, div.large-thumb
	{mso-style-name:large-thumb;
	margin:1.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.small-thumb-canvas, li.small-thumb-canvas, div.small-thumb-canvas
	{mso-style-name:small-thumb-canvas;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.small-thumb, li.small-thumb, div.small-thumb
	{mso-style-name:small-thumb;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup-sensitive-area, li.figpopup-sensitive-area, div.figpopup-sensitive-area
	{mso-style-name:figpopup-sensitive-area;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.print-view, li.print-view, div.print-view
	{mso-style-name:print-view;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.citationexporter-header, li.citationexporter-header, div.citationexporter-header
	{mso-style-name:citationexporter-header;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-style:italic;}
p.citationexporter-footer, li.citationexporter-footer, div.citationexporter-footer
	{mso-style-name:citationexporter-footer;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxpreview, li.mathjaxpreview, div.mathjaxpreview
	{mso-style-name:mathjax_preview;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#888888;}
p.mathjaxerror, li.mathjaxerror, div.mathjaxerror
	{mso-style-name:mathjax_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CC0000;
	font-style:italic;}
p.mathjaxmenu, li.mathjaxmenu, div.mathjaxmenu
	{mso-style-name:mathjax_menu;
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;}
p.mathjaxmenuitem, li.mathjaxmenuitem, div.mathjaxmenuitem
	{mso-style-name:mathjax_menuitem;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxmenuarrow, li.mathjaxmenuarrow, div.mathjaxmenuarrow
	{mso-style-name:mathjax_menuarrow;
	margin-right:0in;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial Unicode MS","serif";
	color:#666666;}
p.mathjaxmenucheck, li.mathjaxmenucheck, div.mathjaxmenucheck
	{mso-style-name:mathjax_menucheck;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS","serif";}
p.mathjaxmenulabel, li.mathjaxmenulabel, div.mathjaxmenulabel
	{mso-style-name:mathjax_menulabel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-style:italic;}
p.mathjaxmenurule, li.mathjaxmenurule, div.mathjaxmenurule
	{mso-style-name:mathjax_menurule;
	margin-top:3.0pt;
	margin-right:.75pt;
	margin-bottom:0in;
	margin-left:.75pt;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxmenuclose, li.mathjaxmenuclose, div.mathjaxmenuclose
	{mso-style-name:mathjax_menuclose;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:18.0pt;
	font-family:"Courier New";
	color:#F0F0F0;}
p.print-log, li.print-log, div.print-log
	{mso-style-name:print-log;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header, li.ui-accordion-header, div.ui-accordion-header
	{mso-style-name:ui-accordion-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons, li.ui-accordion-icons, div.ui-accordion-icons
	{mso-style-name:ui-accordion-icons;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-content, li.ui-accordion-content, div.ui-accordion-content
	{mso-style-name:ui-accordion-content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text, li.ui-button-text, div.ui-button-text
	{mso-style-name:ui-button-text;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header, li.ui-datepicker-header, div.ui-datepicker-header
	{mso-style-name:ui-datepicker-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-next, li.ui-datepicker-next, div.ui-datepicker-next
	{mso-style-name:ui-datepicker-next;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-prev, li.ui-datepicker-prev, div.ui-datepicker-prev
	{mso-style-name:ui-datepicker-prev;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-title, li.ui-datepicker-title, div.ui-datepicker-title
	{mso-style-name:ui-datepicker-title;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane, li.ui-datepicker-buttonpane, div.ui-datepicker-buttonpane
	{mso-style-name:ui-datepicker-buttonpane;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group, li.ui-datepicker-group, div.ui-datepicker-group
	{mso-style-name:ui-datepicker-group;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-title, li.ui-dialog-title, div.ui-dialog-title
	{mso-style-name:ui-dialog-title;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-buttonpane, li.ui-dialog-buttonpane, div.ui-dialog-buttonpane
	{mso-style-name:ui-dialog-buttonpane;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-item, li.ui-menu-item, div.ui-menu-item
	{mso-style-name:ui-menu-item;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-divider, li.ui-menu-divider, div.ui-menu-divider
	{mso-style-name:ui-menu-divider;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value, li.ui-progressbar-value, div.ui-progressbar-value
	{mso-style-name:ui-progressbar-value;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-overlay, li.ui-progressbar-overlay, div.ui-progressbar-overlay
	{mso-style-name:ui-progressbar-overlay;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle, li.ui-slider-handle, div.ui-slider-handle
	{mso-style-name:ui-slider-handle;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range, li.ui-slider-range, div.ui-slider-range
	{mso-style-name:ui-slider-range;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-nav, li.ui-tabs-nav, div.ui-tabs-nav
	{mso-style-name:ui-tabs-nav;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-panel, li.ui-tabs-panel, div.ui-tabs-panel
	{mso-style-name:ui-tabs-panel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-hide, li.ui-tabs-hide, div.ui-tabs-hide
	{mso-style-name:ui-tabs-hide;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-titlebar-close, li.ui-dialog-titlebar-close, div.ui-dialog-titlebar-close
	{mso-style-name:ui-dialog-titlebar-close;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-content, li.ui-dialog-content, div.ui-dialog-content
	{mso-style-name:ui-dialog-content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref-right, li.ui-ncbiautocomplete-link-pref-right, div.ui-ncbiautocomplete-link-pref-right
	{mso-style-name:ui-ncbiautocomplete-link-pref-right;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary, li.ui-button-icon-primary, div.ui-button-icon-primary
	{mso-style-name:ui-button-icon-primary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary, li.ui-button-icon-secondary, div.ui-button-icon-secondary
	{mso-style-name:ui-button-icon-secondary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.prev, li.prev, div.prev
	{mso-style-name:prev;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.next, li.next, div.next
	{mso-style-name:next;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-row-count, li.ui-ncbigrid-select-row-count, div.ui-ncbigrid-select-row-count
	{mso-style-name:ui-ncbigrid-select-row-count;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenulia, li.ui-ncbibasicmenulia, div.ui-ncbibasicmenulia
	{mso-style-name:ui-ncbibasicmenu>li>a;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbimenu-item-leaf, li.ui-ncbimenu-item-leaf, div.ui-ncbimenu-item-leaf
	{mso-style-name:ui-ncbimenu-item-leaf;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.brieflinkpop, li.brieflinkpop, div.brieflinkpop
	{mso-style-name:brieflinkpop;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.star, li.star, div.star
	{mso-style-name:star;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbisetswitch, li.jig-ncbisetswitch, div.jig-ncbisetswitch
	{mso-style-name:jig-ncbisetswitch;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-button, li.ui-ncbisetswitch-button, div.ui-ncbisetswitch-button
	{mso-style-name:ui-ncbisetswitch-button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-options, li.ui-ncbisetswitch-options, div.ui-ncbisetswitch-options
	{mso-style-name:ui-ncbisetswitch-options;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.boxed-text-box, li.boxed-text-box, div.boxed-text-box
	{mso-style-name:boxed-text-box;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-from, li.cell-from, div.cell-from
	{mso-style-name:cell-from;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-citation, li.cell-citation, div.cell-citation
	{mso-style-name:cell-citation;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup, li.figpopup, div.figpopup
	{mso-style-name:figpopup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.button, li.button, div.button
	{mso-style-name:button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.retraction, li.retraction, div.retraction
	{mso-style-name:retraction;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverarrow, li.mathjaxhoverarrow, div.mathjaxhoverarrow
	{mso-style-name:mathjax_hover_arrow;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pbody, li.pbody, div.pbody
	{mso-style-name:pbody;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box, li.page-box, div.page-box
	{mso-style-name:page-box;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box-wide, li.page-box-wide, div.page-box-wide
	{mso-style-name:page-box-wide;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nomaxwidth, li.nomaxwidth, div.nomaxwidth
	{mso-style-name:no_max_width;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.f, li.f, div.f
	{mso-style-name:f;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.l, li.l, div.l
	{mso-style-name:l;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header-icon, li.ui-accordion-header-icon, div.ui-accordion-header-icon
	{mso-style-name:ui-accordion-header-icon;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-optgroup, li.ui-selectmenu-optgroup, div.ui-selectmenu-optgroup
	{mso-style-name:ui-selectmenu-optgroup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-anchor, li.ui-tabs-anchor, div.ui-tabs-anchor
	{mso-style-name:ui-tabs-anchor;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-submit, li.ui-ncbibutton-submit, div.ui-ncbibutton-submit
	{mso-style-name:ui-ncbibutton-submit;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-cancel, li.ui-ncbibutton-cancel, div.ui-ncbibutton-cancel
	{mso-style-name:ui-ncbibutton-cancel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ltd-hover, li.ltd-hover, div.ltd-hover
	{mso-style-name:ltd-hover;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.warn, li.warn, div.warn
	{mso-style-name:warn;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notice, li.notice, div.notice
	{mso-style-name:notice;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content, li.content, div.content
	{mso-style-name:content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.onelinesource, li.onelinesource, div.onelinesource
	{mso-style-name:one_line_source;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tertiary, li.tertiary, div.tertiary
	{mso-style-name:tertiary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverframe, li.mathjaxhoverframe, div.mathjaxhoverframe
	{mso-style-name:mathjax_hover_frame;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.other-issues
	{mso-style-name:other-issues;}
span.underline
	{mso-style-name:underline;}
span.double-underline
	{mso-style-name:double-underline;}
span.bold-double-underline
	{mso-style-name:bold-double-underline;}
span.ui-icon1
	{mso-style-name:ui-icon1;
	display:none;}
span.ui-selectmenu-text
	{mso-style-name:ui-selectmenu-text;}
span.pagelink
	{mso-style-name:page_link;}
span.ui-icon-plus-minus-big
	{mso-style-name:ui-icon-plus-minus-big;}
span.ui-icon-plus-minus-big-open
	{mso-style-name:ui-icon-plus-minus-big-open;}
span.collapsabletbodyicon
	{mso-style-name:collapsabletbodyicon;}
p.ui-accordion-header1, li.ui-accordion-header1, div.ui-accordion-header1
	{mso-style-name:ui-accordion-header1;
	margin-top:1.5pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons1, li.ui-accordion-icons1, div.ui-accordion-icons1
	{mso-style-name:ui-accordion-icons1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons2, li.ui-accordion-icons2, div.ui-accordion-icons2
	{mso-style-name:ui-accordion-icons2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header-icon1, li.ui-accordion-header-icon1, div.ui-accordion-header-icon1
	{mso-style-name:ui-accordion-header-icon1;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-content1, li.ui-accordion-content1, div.ui-accordion-content1
	{mso-style-name:ui-accordion-content1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text1, li.ui-button-text1, div.ui-button-text1
	{mso-style-name:ui-button-text1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text2, li.ui-button-text2, div.ui-button-text2
	{mso-style-name:ui-button-text2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text3, li.ui-button-text3, div.ui-button-text3
	{mso-style-name:ui-button-text3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon2, li.ui-icon2, div.ui-icon2
	{mso-style-name:ui-icon2;
	margin-top:0in;
	margin-right:0in;
	margin-left:-6.0pt;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button1, li.ui-button1, div.ui-button1
	{mso-style-name:ui-button1;
	margin-right:-.05in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header1, li.ui-datepicker-header1, div.ui-datepicker-header1
	{mso-style-name:ui-datepicker-header1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-next1, li.ui-datepicker-next1, div.ui-datepicker-next1
	{mso-style-name:ui-datepicker-next1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-prev1, li.ui-datepicker-prev1, div.ui-datepicker-prev1
	{mso-style-name:ui-datepicker-prev1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-title1, li.ui-datepicker-title1, div.ui-datepicker-title1
	{mso-style-name:ui-datepicker-title1;
	margin-top:0in;
	margin-right:27.6pt;
	margin-bottom:0in;
	margin-left:27.6pt;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:21.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane1, li.ui-datepicker-buttonpane1, div.ui-datepicker-buttonpane1
	{mso-style-name:ui-datepicker-buttonpane1;
	margin-top:8.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group1, li.ui-datepicker-group1, div.ui-datepicker-group1
	{mso-style-name:ui-datepicker-group1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group2, li.ui-datepicker-group2, div.ui-datepicker-group2
	{mso-style-name:ui-datepicker-group2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group3, li.ui-datepicker-group3, div.ui-datepicker-group3
	{mso-style-name:ui-datepicker-group3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header2, li.ui-datepicker-header2, div.ui-datepicker-header2
	{mso-style-name:ui-datepicker-header2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header3, li.ui-datepicker-header3, div.ui-datepicker-header3
	{mso-style-name:ui-datepicker-header3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane2, li.ui-datepicker-buttonpane2, div.ui-datepicker-buttonpane2
	{mso-style-name:ui-datepicker-buttonpane2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane3, li.ui-datepicker-buttonpane3, div.ui-datepicker-buttonpane3
	{mso-style-name:ui-datepicker-buttonpane3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header4, li.ui-datepicker-header4, div.ui-datepicker-header4
	{mso-style-name:ui-datepicker-header4;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header5, li.ui-datepicker-header5, div.ui-datepicker-header5
	{mso-style-name:ui-datepicker-header5;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-title1, li.ui-dialog-title1, div.ui-dialog-title1
	{mso-style-name:ui-dialog-title1;
	margin-top:1.2pt;
	margin-right:12.0pt;
	margin-bottom:2.4pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-buttonpane1, li.ui-dialog-buttonpane1, div.ui-dialog-buttonpane1
	{mso-style-name:ui-dialog-buttonpane1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-left:0in;
	background:whitesmoke;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-item1, li.ui-menu-item1, div.ui-menu-item1
	{mso-style-name:ui-menu-item1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-divider1, li.ui-menu-divider1, div.ui-menu-divider1
	{mso-style-name:ui-menu-divider1;
	margin-top:3.75pt;
	margin-right:0in;
	margin-bottom:3.75pt;
	margin-left:0in;
	line-height:0%;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-active1, li.ui-state-active1, div.ui-state-active1
	{mso-style-name:ui-state-active1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-focus1, li.ui-state-focus1, div.ui-state-focus1
	{mso-style-name:ui-state-focus1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-menu-item2, li.ui-menu-item2, div.ui-menu-item2
	{mso-style-name:ui-menu-item2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon3, li.ui-icon3, div.ui-icon3
	{mso-style-name:ui-icon3;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value1, li.ui-progressbar-value1, div.ui-progressbar-value1
	{mso-style-name:ui-progressbar-value1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-overlay1, li.ui-progressbar-overlay1, div.ui-progressbar-overlay1
	{mso-style-name:ui-progressbar-overlay1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value2, li.ui-progressbar-value2, div.ui-progressbar-value2
	{mso-style-name:ui-progressbar-value2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-handle1, li.ui-resizable-handle1, div.ui-resizable-handle1
	{mso-style-name:ui-resizable-handle1;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-resizable-handle2, li.ui-resizable-handle2, div.ui-resizable-handle2
	{mso-style-name:ui-resizable-handle2;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-menu1, li.ui-menu1, div.ui-menu1
	{mso-style-name:ui-menu1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-optgroup1, li.ui-selectmenu-optgroup1, div.ui-selectmenu-optgroup1
	{mso-style-name:ui-selectmenu-optgroup1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.ui-icon4
	{mso-style-name:ui-icon4;
	display:none;}
span.ui-selectmenu-text1
	{mso-style-name:ui-selectmenu-text1;
	display:none;}
p.ui-slider-handle1, li.ui-slider-handle1, div.ui-slider-handle1
	{mso-style-name:ui-slider-handle1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range1, li.ui-slider-range1, div.ui-slider-range1
	{mso-style-name:ui-slider-range1;
	margin-right:0in;
	margin-left:0in;
	font-size:8.5pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle2, li.ui-slider-handle2, div.ui-slider-handle2
	{mso-style-name:ui-slider-handle2;
	margin-right:0in;
	margin-left:-.1in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle3, li.ui-slider-handle3, div.ui-slider-handle3
	{mso-style-name:ui-slider-handle3;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range2, li.ui-slider-range2, div.ui-slider-range2
	{mso-style-name:ui-slider-range2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon5, li.ui-icon5, div.ui-icon5
	{mso-style-name:ui-icon5;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-anchor1, li.ui-tabs-anchor1, div.ui-tabs-anchor1
	{mso-style-name:ui-tabs-anchor1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tooltip1, li.ui-tooltip1, div.ui-tooltip1
	{mso-style-name:ui-tooltip1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget1, li.ui-widget1, div.ui-widget1
	{mso-style-name:ui-widget1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.ui-state-default1, li.ui-state-default1, div.ui-state-default1
	{mso-style-name:ui-state-default1;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-default2, li.ui-state-default2, div.ui-state-default2
	{mso-style-name:ui-state-default2;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-focus2, li.ui-state-focus2, div.ui-state-focus2
	{mso-style-name:ui-state-focus2;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover1, li.ui-state-hover1, div.ui-state-hover1
	{mso-style-name:ui-state-hover1;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-focus3, li.ui-state-focus3, div.ui-state-focus3
	{mso-style-name:ui-state-focus3;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover2, li.ui-state-hover2, div.ui-state-hover2
	{mso-style-name:ui-state-hover2;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active2, li.ui-state-active2, div.ui-state-active2
	{mso-style-name:ui-state-active2;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active3, li.ui-state-active3, div.ui-state-active3
	{mso-style-name:ui-state-active3;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-highlight1, li.ui-state-highlight1, div.ui-state-highlight1
	{mso-style-name:ui-state-highlight1;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-highlight2, li.ui-state-highlight2, div.ui-state-highlight2
	{mso-style-name:ui-state-highlight2;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-error1, li.ui-state-error1, div.ui-state-error1
	{mso-style-name:ui-state-error1;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error2, li.ui-state-error2, div.ui-state-error2
	{mso-style-name:ui-state-error2;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text1, li.ui-state-error-text1, div.ui-state-error-text1
	{mso-style-name:ui-state-error-text1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text2, li.ui-state-error-text2, div.ui-state-error-text2
	{mso-style-name:ui-state-error-text2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-priority-primary1, li.ui-priority-primary1, div.ui-priority-primary1
	{mso-style-name:ui-priority-primary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-primary2, li.ui-priority-primary2, div.ui-priority-primary2
	{mso-style-name:ui-priority-primary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-secondary1, li.ui-priority-secondary1, div.ui-priority-secondary1
	{mso-style-name:ui-priority-secondary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-priority-secondary2, li.ui-priority-secondary2, div.ui-priority-secondary2
	{mso-style-name:ui-priority-secondary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled1, li.ui-state-disabled1, div.ui-state-disabled1
	{mso-style-name:ui-state-disabled1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled2, li.ui-state-disabled2, div.ui-state-disabled2
	{mso-style-name:ui-state-disabled2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon6, li.ui-icon6, div.ui-icon6
	{mso-style-name:ui-icon6;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon7, li.ui-icon7, div.ui-icon7
	{mso-style-name:ui-icon7;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon8, li.ui-icon8, div.ui-icon8
	{mso-style-name:ui-icon8;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon9, li.ui-icon9, div.ui-icon9
	{mso-style-name:ui-icon9;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon10, li.ui-icon10, div.ui-icon10
	{mso-style-name:ui-icon10;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon11, li.ui-icon11, div.ui-icon11
	{mso-style-name:ui-icon11;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon12, li.ui-icon12, div.ui-icon12
	{mso-style-name:ui-icon12;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon13, li.ui-icon13, div.ui-icon13
	{mso-style-name:ui-icon13;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon14, li.ui-icon14, div.ui-icon14
	{mso-style-name:ui-icon14;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-nav1, li.ui-tabs-nav1, div.ui-tabs-nav1
	{mso-style-name:ui-tabs-nav1;
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tertiary1, li.tertiary1, div.tertiary1
	{mso-style-name:tertiary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#666666;}
p.tertiary2, li.tertiary2, div.tertiary2
	{mso-style-name:tertiary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#985735;}
p.ui-tabs-panel1, li.ui-tabs-panel1, div.ui-tabs-panel1
	{mso-style-name:ui-tabs-panel1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-hide1, li.ui-tabs-hide1, div.ui-tabs-hide1
	{mso-style-name:ui-tabs-hide1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-dialog-titlebar1, li.ui-dialog-titlebar1, div.ui-dialog-titlebar1
	{mso-style-name:ui-dialog-titlebar1;
	margin-right:0in;
	margin-left:0in;
	background:#3E72A6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.ui-dialog-titlebar-close1, li.ui-dialog-titlebar-close1, div.ui-dialog-titlebar-close1
	{mso-style-name:ui-dialog-titlebar-close1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-content1, li.ui-dialog-content1, div.ui-dialog-content1
	{mso-style-name:ui-dialog-content1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-se1, li.ui-resizable-se1, div.ui-resizable-se1
	{mso-style-name:ui-resizable-se1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon15, li.ui-icon15, div.ui-icon15
	{mso-style-name:ui-icon15;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-hover3, li.ui-state-hover3, div.ui-state-hover3
	{mso-style-name:ui-state-hover3;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-ncbibutton-submit1, li.ui-ncbibutton-submit1, div.ui-ncbibutton-submit1
	{mso-style-name:ui-ncbibutton-submit1;
	margin-right:6.55pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-cancel1, li.ui-ncbibutton-cancel1, div.ui-ncbibutton-cancel1
	{mso-style-name:ui-ncbibutton-cancel1;
	margin-right:0in;
	margin-left:0in;
	line-height:22.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#2F4A8B;}
p.ui-button-text4, li.ui-button-text4, div.ui-button-text4
	{mso-style-name:ui-button-text4;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref-right1, li.ui-ncbiautocomplete-link-pref-right1, div.ui-ncbiautocomplete-link-pref-right1
	{mso-style-name:ui-ncbiautocomplete-link-pref-right1;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text5, li.ui-button-text5, div.ui-button-text5
	{mso-style-name:ui-button-text5;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text6, li.ui-button-text6, div.ui-button-text6
	{mso-style-name:ui-button-text6;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text7, li.ui-button-text7, div.ui-button-text7
	{mso-style-name:ui-button-text7;
	margin-right:0in;
	margin-left:0in;
	text-indent:595.95pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text8, li.ui-button-text8, div.ui-button-text8
	{mso-style-name:ui-button-text8;
	margin-right:0in;
	margin-left:0in;
	text-indent:595.95pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text9, li.ui-button-text9, div.ui-button-text9
	{mso-style-name:ui-button-text9;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text10, li.ui-button-text10, div.ui-button-text10
	{mso-style-name:ui-button-text10;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon16, li.ui-icon16, div.ui-icon16
	{mso-style-name:ui-icon16;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon17, li.ui-icon17, div.ui-icon17
	{mso-style-name:ui-icon17;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon18, li.ui-icon18, div.ui-icon18
	{mso-style-name:ui-icon18;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon19, li.ui-icon19, div.ui-icon19
	{mso-style-name:ui-icon19;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon20, li.ui-icon20, div.ui-icon20
	{mso-style-name:ui-icon20;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon21, li.ui-icon21, div.ui-icon21
	{mso-style-name:ui-icon21;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary1, li.ui-button-icon-primary1, div.ui-button-icon-primary1
	{mso-style-name:ui-button-icon-primary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary2, li.ui-button-icon-primary2, div.ui-button-icon-primary2
	{mso-style-name:ui-button-icon-primary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary3, li.ui-button-icon-primary3, div.ui-button-icon-primary3
	{mso-style-name:ui-button-icon-primary3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary1, li.ui-button-icon-secondary1, div.ui-button-icon-secondary1
	{mso-style-name:ui-button-icon-secondary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary2, li.ui-button-icon-secondary2, div.ui-button-icon-secondary2
	{mso-style-name:ui-button-icon-secondary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-pagecontrol1, li.ui-ncbigrid-paged-pagecontrol1, div.ui-ncbigrid-paged-pagecontrol1
	{mso-style-name:ui-ncbigrid-paged-pagecontrol1;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.prev1, li.prev1, div.prev1
	{mso-style-name:prev1;
	margin-right:.1in;
	margin-left:2.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.next1, li.next1, div.next1
	{mso-style-name:next1;
	margin-right:2.4pt;
	margin-left:.1in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-row-count1, li.ui-ncbigrid-select-row-count1, div.ui-ncbigrid-select-row-count1
	{mso-style-name:ui-ncbigrid-select-row-count1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.pagelink1
	{mso-style-name:page_link1;
	color:#CCCCCC;}
span.collapsabletbodyicon1
	{mso-style-name:collapsabletbodyicon1;}
span.ui-icon-plus-minus-big1
	{mso-style-name:ui-icon-plus-minus-big1;}
span.ui-icon-plus-minus-big-open1
	{mso-style-name:ui-icon-plus-minus-big-open1;}
p.ui-ncbigrid-outer-div1, li.ui-ncbigrid-outer-div1, div.ui-ncbigrid-outer-div1
	{mso-style-name:ui-ncbigrid-outer-div1;
	margin:0in;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbimenu-item-leaf1, li.ui-ncbimenu-item-leaf1, div.ui-ncbimenu-item-leaf1
	{mso-style-name:ui-ncbimenu-item-leaf1;
	margin-top:0in;
	margin-right:9.0pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.brieflinkpop1, li.brieflinkpop1, div.brieflinkpop1
	{mso-style-name:brieflinkpop1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.ui-icon-plus-minus-big2
	{mso-style-name:ui-icon-plus-minus-big2;}
span.ui-icon-plus-minus-big-open2
	{mso-style-name:ui-icon-plus-minus-big-open2;}
span.ui-icon22
	{mso-style-name:ui-icon22;
	display:none;}
span.ui-icon23
	{mso-style-name:ui-icon23;
	display:none;}
p.star1, li.star1, div.star1
	{mso-style-name:star1;
	margin-right:7.4pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbisetswitch1, li.jig-ncbisetswitch1, div.jig-ncbisetswitch1
	{mso-style-name:jig-ncbisetswitch1;
	margin-right:0in;
	margin-left:0in;
	line-height:14.75pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#333333;}
p.ui-ncbisetswitch-button1, li.ui-ncbisetswitch-button1, div.ui-ncbisetswitch-button1
	{mso-style-name:ui-ncbisetswitch-button1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon24, li.ui-icon24, div.ui-icon24
	{mso-style-name:ui-icon24;
	margin:5.55pt;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ltd-hover1, li.ltd-hover1, div.ltd-hover1
	{mso-style-name:ltd-hover1;
	margin-right:0in;
	margin-left:0in;
	background:#E8E8E8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon25, li.ui-icon25, div.ui-icon25
	{mso-style-name:ui-icon25;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-options1, li.ui-ncbisetswitch-options1, div.ui-ncbisetswitch-options1
	{mso-style-name:ui-ncbisetswitch-options1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pbody1, li.pbody1, div.pbody1
	{mso-style-name:pbody1;
	margin-top:0in;
	margin-right:16.6pt;
	margin-bottom:0in;
	margin-left:16.6pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box1, li.page-box1, div.page-box1
	{mso-style-name:page-box1;
	margin-top:16.6pt;
	margin-right:0in;
	margin-bottom:16.6pt;
	margin-left:0in;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box-wide1, li.page-box-wide1, div.page-box-wide1
	{mso-style-name:page-box-wide1;
	margin-top:16.6pt;
	margin-right:0in;
	margin-bottom:16.6pt;
	margin-left:0in;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nomaxwidth1, li.nomaxwidth1, div.nomaxwidth1
	{mso-style-name:no_max_width1;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content1, li.content1, div.content1
	{mso-style-name:content1;
	margin:16.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.boxed-text-box1, li.boxed-text-box1, div.boxed-text-box1
	{mso-style-name:boxed-text-box1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.f1, li.f1, div.f1
	{mso-style-name:f1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.l1, li.l1, div.l1
	{mso-style-name:l1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-from1, li.cell-from1, div.cell-from1
	{mso-style-name:cell-from1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.cell-citation1, li.cell-citation1, div.cell-citation1
	{mso-style-name:cell-citation1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup1, li.figpopup1, div.figpopup1
	{mso-style-name:figpopup1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.button1, li.button1, div.button1
	{mso-style-name:button1;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#336699;}
p.retraction1, li.retraction1, div.retraction1
	{mso-style-name:retraction1;
	margin-right:0in;
	margin-left:0in;
	background:red;
	font-size:12.0pt;
	font-family:"Helvetica","sans-serif";
	color:#F0F0F0;}
p.warn1, li.warn1, div.warn1
	{mso-style-name:warn1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notice1, li.notice1, div.notice1
	{mso-style-name:notice1;
	margin-right:0in;
	margin-left:0in;
	font-size:16.5pt;
	font-family:"Times New Roman","serif";}
p.arrowtab1, li.arrowtab1, div.arrowtab1
	{mso-style-name:arrowtab1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.thistab1, li.thistab1, div.thistab1
	{mso-style-name:thistab1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F6F6F6;
	border:none;
	padding:0in;
	font-size:9.5pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;}
p.onelinesource1, li.onelinesource1, div.onelinesource1
	{mso-style-name:one_line_source1;
	margin-right:0in;
	margin-left:0in;
	background:#E0E0E0;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverarrow1, li.mathjaxhoverarrow1, div.mathjaxhoverarrow1
	{mso-style-name:mathjax_hover_arrow1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:7.0pt;
	font-family:"Courier New";
	color:#F0F0F0;}
p.mathjaxmenuarrow1, li.mathjaxmenuarrow1, div.mathjaxmenuarrow1
	{mso-style-name:mathjax_menuarrow1;
	margin-right:0in;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial Unicode MS","serif";
	color:white;}
span.cit
	{mso-style-name:cit;}
span.fm-vol-iss-date
	{mso-style-name:fm-vol-iss-date;}
span.doi1
	{mso-style-name:doi1;}
span.fm-citation-ids-label
	{mso-style-name:fm-citation-ids-label;}
span.before-email-separator
	{mso-style-name:before-email-separator;}
span.email-label
	{mso-style-name:email-label;}
p.p, li.p, div.p
	{mso-style-name:p;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.kwd-text
	{mso-style-name:kwd-text;}
span.small-caps
	{mso-style-name:small-caps;}
span.tag-json
	{mso-style-name:tag-json;}
span.citation
	{mso-style-name:citation;}
span.ref-journal
	{mso-style-name:ref-journal;}
span.ref-vol
	{mso-style-name:ref-vol;}
span.nowrap
	{mso-style-name:nowrap;}
span.ref-title
	{mso-style-name:ref-title;}
span.acknowledgment-journal-title
	{mso-style-name:acknowledgment-journal-title;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma","sans-serif";}
.MsoChpDefault
	{font-family:"Calibri","sans-serif";}
.MsoPapDefault
	{margin-bottom:10.0pt;
	line-height:115%;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple>

<div class=WordSection1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Br
J Cancer. 2005 Jun 6; 92(11): 20322038. </span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Published
online 2005 May 31. doi:&nbsp; </span><a
href="http://dx.doi.org/10.1038%2Fsj.bjc.6602598" target="pmc_ext"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>10.1038/sj.bjc.6602598</span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMCID:
PMC2361800</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:24.0pt;font-family:"Times New Roman","serif"'>Activation of
the MAPK pathway is a common event in uveal melanomas although it rarely occurs
through mutation of <i>BRAF</i> or <i>RAS</i></span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Zuidervaart%20W%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>W
Zuidervaart</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>1</sup>
</span><a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=van%20Nieuwpoort%20F%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>F van
Nieuwpoort</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>2</sup>
</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Stark%20M%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>M Stark</span></a><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>3</sup>
</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Dijkman%20R%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>R
Dijkman</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>2</sup>
</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Packer%20L%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>L Packer</span></a><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>3</sup>
</span><a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Borgstein%20AM%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>A-M
Borgstein</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>2</sup>
</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Pavey%20S%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>S Pavey</span></a><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>3</sup>
</span><a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=van%20der%20Velden%20P%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>P van
der Velden</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>2</sup>
</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Out%20C%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>C Out</span></a><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>2</sup>
</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Jager%20MJ%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>M J
Jager</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>1</sup>
</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Hayward%20NK%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>N K
Hayward</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,<sup>3</sup>
and </span><a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Gruis%20NA%5Bauth%5D"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>N A
Gruis</span></a><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>2,*</span></sup></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>1</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Ophthalmology, Leiden
University Medical Centre, PO Box 9600, 2300 RC, Leiden, The Netherlands</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>2</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Dermatology, Leiden
University Medical Centre, Wassenaarseweg 72, 2333 AL, Leiden, The Netherlands</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>3</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Queensland Institute of Medical
Research, 300 Herston Rd, Herston, QLD 4029, Australia</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>*</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Author for correspondence: Email: </span><a
href="mailto:dev@null"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>ln.cmul@siurg</span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Author
information &#9658;</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'> </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Article notes
&#9658;</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Copyright
and License information &#9658;</span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Received 2004 Dec 1; Revised 2005 Mar 10; Accepted 2005 Mar 24.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Copyright</span></a><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif";display:none'> 2005, Cancer Research UK</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>This
article has been </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/citedby/"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>cited by</span></a><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'> other
articles in PMC.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/"
title="Go to other sections in this page"><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>Go to:</span></a></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>Abstract</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>In contrast to cutaneous
melanoma, there is no evidence that <i>BRAF</i> mutations are involved in the
activation of the mitogen-activated protein kinase (MAPK) pathway in uveal
melanoma, although there is increasing evidence that this pathway is activated
frequently in the latter tumours. <span style='background:yellow'>In this
study, we performed mutation analysis of the <i>RAS</i> and <i>BRAF</i> genes
in a panel of 11 uveal melanoma cell lines and 19 primary uveal melanoma
tumours.</span> <span style='background:yellow'>In addition, Western blot and
immunohistochemical analyses were performed on downstream members of the MAPK
pathway in order to assess the contribution of each of these components.</span>
<span style='background:yellow'>No mutations were found in any of the three RAS
gene family members and only one cell line carried a <i>BRAF</i> mutation
(V599E).</span> <span style='background:yellow'>Despite this, mitogen-activated
protein kinase/extracellular signal-regulated kinase kinase (MEK), ERK and ELK
were constitutively activated in all samples</span>. These data suggest that
activation of the MAPK pathway is commonly involved in the development of uveal
melanoma, but occurs through a mechanism different to that of cutaneous
melanoma.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Keywords:
</span></b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>MAPK
pathway, uveal melanoma, <i>BRAF</i>, <i>RAS</i>, mutation</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Uveal melanoma is the most common
primary intraocular tumour in adults, with an annual incidence of 68 new cases
per million among Caucasian populations. Up to half of all patients die from
metastatic disease (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib10"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Diener-West
<i>et al</i>, 1992</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>). In spite of several known prognostic markers
(pathologic and genetic), such as tumour cell type, diameter, localisation and
cytogenetic abnormalities, little is known about specific genes associated with
predisposition and progression in uveal melanoma (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib23"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Mooy and
de Jong, 1996</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib34"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Sisley <i>et
al</i>, 1997</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).
Notable exceptions are hypermethylation of <i>CDKN2A</i>, which is more common
in tumours from patients who develop metastatic disease (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib40"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>van der
Velden <i>et al</i>, 2001</span></a><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>), and germline <i>BRCA2</i> gene
mutations, which occur in 3% of patients younger than 50 years of age (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib31"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Scott <i>et
al</i>, 2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).
Hence, the search for other genes and molecular pathways involved in uveal
melanoma development is of great significance. In contrast to uveal melanoma,
the influence of specific pathways in cutaneous melanoma, which shares the same
embryonic origin, is better defined. For instance, the tumour suppressor gene <i>PTEN</i>,
encoding a dual-specific phosphatase and a member of the PI3-AKT pathway, plays
a major role in the pathogenesis of cutaneous melanoma (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib15"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Guldberg
<i>et al</i>, 1997</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>; </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib36"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Stahl <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>),
whereas no mutations in this gene have been found in uveal melanoma (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib25"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Naus <i>et
al</i>, 2000</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:lime'>Recently, the
RAS-RAF-MEK-ERK or mitogen-activated protein kinase (MAPK) pathway has been
found to play an important role in melanocytic neoplasia</span><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'> (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib6"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cohen <i>et al</i>,
2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib30"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Satyamoorthy
<i>et al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>). Activation of this pathway in cutaneous
melanocytes has been shown to occur by a variety of mechanisms, including
autocrine growth factor stimulation and mutation of the <i>RAS</i> or <i>BRAF</i>
genes. <span style='background:lime'>Of three <i>RAS</i> genes found to be
activated by mutation in human tumours, <i>NRAS</i> (neuroblastoma RAS viral
(v-<i>ras</i>) oncogene homologue) is most commonly mutated in cutaneous
melanomas (</span></span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib41"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
background:lime'>van Elsas <i>et al</i>, 1996</span></a><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";background:lime'>).</span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'> In the
active GTP-bound state, RAS activates a number of downstream signalling
cascades involved in controlling cell growth and behaviour. <span
style='background:lime'>Initially, RAS interacts with and activates the
serine/threonine protein kinase BRAF that acts in the MAPK pathway to transduce
regulatory signals from RAS to mitogen-activated protein kinase/extracellular
signal-related kinase kinase (MEK1/2).</span> <span style='background:lime'>The
signal transducer MEK1/2 phosphorylates extracellular signal-regulated kinase
(ERK1/2, p44/42), leading to the activation of these kinases, which in turn
activate a variety of transcription factors, including ELK1, again through
phosphorylation.</span> It has emerged that <i>BRAF</i> (v-<i>raf</i> murine
sarcoma viral oncogene homologue B1) is very frequently activated by mutation
in cutaneous melanomas (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib2"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Brose <i>et al</i>,
2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib8"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Davies <i>et
al</i>, 2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib1"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Alsina <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib11"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Dong <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib13"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Gorden <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib18"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Kumar <i>et
al</i>, 2003a</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib19"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>2003b</span></a><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>; </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib21"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Maldonado
<i>et al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>; </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib26"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Omholt <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib27"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Pollock <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib29"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Rimoldi <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib30"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Satyamoorthy
<i>et al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>; </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib42"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Weber <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib5"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cohen <i>et
al</i>, 2004</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib28"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Reifenberger
<i>et al</i>, 2004</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>; </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib33"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Shinozaki
<i>et al</i>, 2004</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>; </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib38"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Tsao <i>et
al</i>, 2004</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).
The frequency of <i>BRAF</i> mutations varies from 8 to 83% depending on the
anatomic site of the lesion and its histogenic subtype. Notably, the frequency
of <i>BRAF</i> mutations is also high in benign melanocytic naevi (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib11"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Dong <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib27"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Pollock <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib39"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Uribe <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib43"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Yazdi <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>),
indicating that constitutive activation of the MAPK pathway is an early event
in melanomagenesis. All <i>BRAF</i> mutations in cutaneous pigmented neoplasms
occur within the kinase domain. The most frequently found mutation in <i>BRAF</i>
(V599E) consists of a 1796T &#8594; A transversion in exon 15 (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib8"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Davies <i>et al</i>,
2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).
Various other mutations have been described in this exon in melanocytic tumours
(V599D (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib2"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Brose <i>et al</i>,
2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib8"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Davies <i>et
al</i>, 2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib27"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Pollock <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>);
V599K (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib27"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Pollock <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib39"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Uribe <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>);
V599R (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib27"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Pollock <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>);
K600E (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib2"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Brose <i>et al</i>,
2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib30"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Satyamoorthy
<i>et al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>)). All other mutations have been described in exon
11. The latter consist of a 1352A &#8594; C transversion (K438Q) (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib2"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Brose <i>et al</i>,
2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>),
a 1402G &#8594; A transition (G468R) and a 1402/1403GG &#8594; TC tandem
transversion (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib13"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Gorden <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>),
a 1394G &#8594; A transition (G465E) and a 1394G &#8594; C transversion (G465A)
(</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib8"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Davies <i>et
al</i>, 2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).
Furthermore, it is not surprising that since they activate the same pathway,
mutations in <i>NRAS</i> and <i>BRAF</i> are almost mutually exclusive (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib2"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Brose <i>et al</i>,
2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib8"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Davies <i>et
al</i>, 2002</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib1"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Alsina <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib11"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Dong <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib13"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Gorden <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib18"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Kumar <i>et
al</i>, 2003a</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>,
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib19"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>2003b</span></a><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>; </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib26"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Omholt <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib27"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Pollock <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib30"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Satyamoorthy
<i>et al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>; </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib28"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Reifenberger
<i>et al</i>, 2004</span></a><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'>; </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib38"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Tsao <i>et
al</i>, 2004</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Since cutaneous and uveal
melanoma both arise from neural crest-derived melanocytes, we sought to assess
whether the MAPK pathway was similarly activated in melanoma of the uvea. <span
style='background:yellow'>We thus screened for activating mutations in the <i>NRAS</i>,
<i>HRAS</i>, <i>KRAS</i> and <i>BRAF</i> genes in uveal melanoma cell lines and
primary uveal melanomas.</span> Sequence analysis was performed on exons 1115
of <i>BRAF</i>, and exons 1 and 2 of the three <i>RAS</i> family members, which
cover the positions of all known mutations of these genes in all types of
cancer. In addition, we performed immunohistochemistry and Western blot
analysis with MEK, ERK and ELK antibodies both on cell lines and/or primary
tumours to assess the level of expression and degree of activation of these
proteins in order to provide insight into the involvement of this pathway in
the development of uveal melanoma.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/"
title="Go to other sections in this page"><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>Go to:</span></a></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>MATERIALS AND METHODS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Cell lines and
primary uveal melanoma specimens </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>In total, 11
uveal melanoma cell lines, derived from primary uveal melanomas (Mel202, Mel
285, Mel 270, Mel 290, Ocm 1, Ocm 3, 92.1, 92.2) or uveal melanoma metastases
(Omm 1 Omm 1.3 and Omm 1.5), were analysed. Mel 202, Mel 285, Mel 270, Mel 290
and the two cell lines derived from
metastases (Omm 1.3 and Omm 1.5) were kindly provided by Dr BR Ksander
(Schepens Eye Institute, Boston, MA, USA).</span> <span style='background:yellow'>Omm
1, obtained from a subcutaneous metastasis, was established by Dr Luyten (Luyten <i>et
al</i>, 1996).</span><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'> <span
style='background:yellow'>The cell lines Ocm 1 and Ocm 3 were provided by Dr
Kan-Mitchell (Kan-Mitchell
<i>et al</i>, 1989) and cell lines 92.1
and 92.2, derived from the same primary tumour were established in our own
laboratory (de
Waard-Siebinga <i>et al</i>, 1995).</span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'> The
melanoma cell lines were cultured in RPMI 1640 (Gibco, Paisley, Scotland)
medium, supplemented with 3&#8201;mM L-glutamine (Gibco), 2%
penicillin/streptomycin and 10% FBS (Hyclone, Logan, UT, USA). All cell
cultures were incubated at 37C in a humidified 5% CO<sub>2</sub> atmosphere.
In addition, we analysed 19 primary fresh frozen uveal melanomas. Of the
primary tumours, eight were located in the choroid and 11 in both the choroid
and ciliary body. Four of these samples showed a spindle cell type, one an
epithelioid cell type and 14 had a mixed population of cells. All samples were
derived from tumours with a diameter greater than 12&#8201;ml and a prominence
greater than 6&#8201;ml. The research protocol followed the tenets of the
Declaration of Helsinki (World Medical Association Declaration of Helsinki
1964; ethical principles for medical research involving human subjects).</span></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Sequencing </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>DNA was extracted from each cell
line using an adaptation of the salting-out method (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib22"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Miller <i>et
al</i>, 1988</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).
Primers used to amplify parts of the <i>BRAF</i> and <i>RAS</i> genes are given
in </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl1/"
target=true><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Table
1</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl1/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=204 height=140 id="Picture 5"
src="PMC2361800%20table%202_files/image001.png" alt="Table 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl1/"
target=table><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Table
1</span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PCR
primers for <i>BRAF</i>, <i>NRAS</i>, <i>KRAS</i> and <i>HRAS</i> genes</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Reactions for <i>BRAF</i>
contained 200 ng of DNA, QIAGEN (Hilden, Germany) PCR buffer (10 
concentrated, containing Tris-Cl, KCl, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>,
15&#8201;mM MgCl<sub>2</sub>; pH 8.7), Q solution (PCR enhancer),
20&#8201;pmol&#8201;<i>&#956;</i>l<sup>&#8722;1</sup> of each primer,
2&#8201;mM of each dNTP and 1.25&#8201;U of QIAGEN <i>Taq</i> polymerase.
Amplification involved 35 cycles of denaturation at 94C for 45&#8201;s,
annealing at 56C for 90&#8201;s, and extension at 72C for 90&#8201;s. An
initial 12&#8201;min denaturation step at 94C and a final 3&#8201;min
extension at 72C were also used. For the <i>RAS</i> genes, DNA was amplified
using QIAGEN <i>Taq</i> polymerase as described above, but PCR involved a
touchdown' thermal cycling routine of two cycles at each annealing
temperature, decreasing by steps of 2C, followed by 25 cycles at the lowest
temperature. Each cycle consisted of denaturation at 94C for 45&#8201;s,
annealing at 6557C for 90&#8201;s and extension at 72C for 90&#8201;s. An
initial 12&#8201;min denaturation at 94C and a final 3&#8201;min extension at
72C were also employed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>From 19 fresh frozen uveal
melanoma samples, total RNA was extracted with RNeasy kits as described by the
manufacturer (QIAGEN). RNA was primed with random primers and reverse
transcribed into cDNA in a 20&#8201;<i>&#956;</i>l reaction volume containing
200&#8201;U Superscript II (MMV) reverse transcriptase (Invitrogen, Inc.,
Breda, The Netherlands). PCR primers used for amplifying parts of the <i>BRAF</i>
and <i>RAS</i> genes in the primary tumour samples are also listed in </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl1/"
target=true><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Table
1</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>.
A touchdown PCR procedure for <i>BRAF</i> was followed as described above and a
fixed annealing temperature of 57C with a total of 38 cycles was used for the <i>RAS</i>
genes followed by a final elongation step of 10&#8201;min.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>PCR products of all samples were
electrophoresed through 1.5% TAE/agarose gels stained with ethidium bromide,
excised and purified using a QIAGEN QIAquick Gel Extraction Kit. The <i>RAS</i>
and <i>BRAF</i> PCR products were sequenced using Applied Biosystems (ABI)
BigDye version 3 reagents according to the manufacturer's instructions using
3.2&#8201;pmol&#8201;<i>&#956;</i>l<sup>&#8722;1</sup> of primer. Sequencing
products were precipitated using 75% isopropanol and were run on an ABI 377
automated sequencer (PE Applied Biosystems, Foster City, CA, USA).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Western blot
analysis </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Protein lysates from the uveal
melanoma cell lines were separated on 12.5% SDSPAGE gels and the proteins
transferred to Hybond-polyvinyldifluoride membranes (Amersham biosciences,
Buckinghamshire, UK). After blocking with 5% skim milk in PBS-Tween solution,
the membranes were probed overnight at 4C with the following primary
antibodies specific to each antigen: phospho-MEK1/2 (dilution
1&#8201;:&#8201;1000), phospho-ERK1/2 (p44/42) (#9106, dilution
1&#8201;:&#8201;5000), total ERK1/2 (#9102, dilution 1&#8201;:&#8201;1000) and
phospho-ELK1 (dilution 1&#8201;:&#8201;1000) antibody (all from Cell Signaling
Technology, Hertfordshire, UK). An antibody against actin (Santa Cruz
Biotechnology, California, USA) was used as a loading control. Membranes were
then incubated with horseradish peroxidase-conjugated IgG anti-mouse,
anti-rabbit or anti-goat secondary antibodies for 1&#8201;h at room temperature
to visualise protein bands.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Immunohistochemistry
</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Acetone-fixed 10&#8201;<i>&#956;</i>m
sections of 19 fresh frozen uveal melanomas were washed three times in PBS
(pH=7.2) and were incubated with anti-ERK1/2 and anti-phospho-ERK 1/2
antibodies (Cell Signalling Technology, Beverly MA, USA, #9102 and #9106,
respectively), both diluted 1&#8201;:&#8201;100 in PBS with 1% BSA and 2%
normal human serum (NHS) at 4C. The sections were washed three times and
incubated with cy3-conjugated AffiniPure goat anti-rabbit IgG or with
cy3-conjugated AffiniPure rabbit anti-mouse IgG (Jackson ImmunoResearch, West
Grove PA, USA #111-165-003 and #315-165-003) both diluted 1&#8201;:&#8201;500,
respectively, during 1&#8201;h at room temperature. Sections were rinsed with
PBS three times and incubated for 20&#8201;min with Alexa Fluor 647 Phalloidin
(Molecular Probes, Leiden, The Netherlands, #</span><a
href="http://www.ncbi.nlm.nih.gov/nuccore/A22287"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none'>{&quot;type&quot;:&quot;entrez-nucleotide&quot;,&quot;attrs&quot;:{&quot;text&quot;:&quot;A22287&quot;,&quot;term_id&quot;:&quot;641467&quot;,&quot;term_text&quot;:&quot;A22287&quot;}}</span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>A22287</span></a><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>) at a
1&#8201;:&#8201;40 dilution. Sections are washed three times with PBS. A
nuclear staining was preformed by incubating the sections for 5&#8201;min with
4&#8242;,6-diamidino-2-phenylindole dilacetate (DAPI, Molecular Probes, Leiden,
The Netherlands, #D-3571) 1&#8201;:&#8201;500. Sections were rinsed briefly in
PBS and imbedded with Vectashield (Vecta Shield H1000, Brunschwig, Amsterdam,
The Netherlands). For each specimen, the fluorescence of cy3 was determined in
three different microscope fields (Leica DMRXA microscope, Leica Microsystems,
Rijswijk, The Netherlands). No background fluorescence of cy3 was observed. The
number of positively stained tumour cells was estimated for the two antibodies
and expressed as the percentage of the total number of tumour cells in the
analysed section. <span style='background:yellow'>Percentages were then
categorised as either negative &lt;5% (+/&#8722;), very weakly positive 525%
(+), weakly positive 2650% (++), moderately positive 5175% (+++) or highly
positive 76100% (++++).</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The slides were examined by two
observers independently. Interobserver disagreement did not exceed one
category.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/"
title="Go to other sections in this page"><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>Go to:</span></a></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>RESULTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Mutation
analysis </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>Of the 11 uveal
melanoma cell lines under study, only one cell line (Ocm 1) carried a <i>BRAF</i>
mutation, the common V599E (also described by Calipel <i>et al</i> and Kilic <i>et
al</i>).</span><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>
<span style='background:yellow'>All primary tumour specimens were wild type for
<i>BRAF</i>.</span> <span style='background:yellow'>No mutations were found in
the <i>NRAS</i>, <i>HRAS</i> or <i>KRAS</i> genes, in both the cell lines and
primary tissue.</span></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Western blotting
</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>In order to
assess the level of expression and the activation (by phosphorylation) of
members of the MAPK pathway downstream of <i>RAS</i> and <i>BRAF</i>, Western
blot analysis was performed on uveal melanoma cell lines (Table 2A).</span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'> The
expression levels of the downstream members of RAS and BRAF are presented in </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/figure/fig1/"
target=figure><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Figure
1</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>.
<span style='background:yellow'>In response to the constitutively activating <i>BRAF</i>
mutation in Ocm 1, downstream members of the MAPK pathway show activation
(phosphorylated MEK, ERK and ELK).</span> <span style='background:yellow'>Levels
of expression of the downstream members were not different in the two cell
lines derived from the same primary tumour (92.1 and 92.2), except for
phosphorylated MEK, indicating that there had been little clonal divergence
between the cell populations during <i>in vitro</i> culturing.</span> <span
style='background:yellow'>Interestingly, compared to the phosphorylation status
of these members in Ocm 1, most cell lines show activation of MEK, ERK and ELK;
however, these cell lines show this activation in the absence of mutations in
the upstream <i>RAS</i> and <i>BRAF</i> genes.</span> <span style='background:yellow'>The levels of total ERK were remarkably similar across all cell lines,
with the exception of two cell lines Mel 285 and Mel 290, which had
significantly higher levels of total ERK than the others.</span> <span
style='background:yellow'>In keeping with this observation, these two cell
lines also have the highest levels of phosphorylated-ERK.</span> </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/figure/fig2/"
target=figure><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Figure
2</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>
shows that there is no significant influence of serum on the activity of ERK1/2
in these cell lines, as reported recently by </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib3"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Calipel <i>et al</i>
(2003)</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/figure/fig1/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=61 id="Picture 4"
src="PMC2361800%20table%202_files/image002.gif" alt="Figure 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/figure/fig1/"
target=figure><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Figure
1</span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Expression
levels of members of the MAPK pathway downstream of RAS and BRAF in 11 uveal
melanoma cell lines. Actin levels were assessed as a loading control.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/figure/fig2/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=35 id="Picture 3"
src="PMC2361800%20table%202_files/image003.gif" alt="Figure 2"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/figure/fig2/"
target=figure><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Figure
2</span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>ERK1/2
and phospho-ERK1/2 expression in uveal melanoma cell lines (Mel 202, Ocm 1, Mel
285, Mel 290) cultured with (+) and without (&#8722;) serum (24&#8201;h). A
similar lack of effect of serum on influencing the level of phospho-ERK1/2 was <b>...</b></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl2/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=204 height=140 id="Picture 2"
src="PMC2361800%20table%202_files/image004.png" alt="Table 2"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl2/"
target=table><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Table
2</span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
background:yellow'>Summary
of mutation analyses, immunohistochemical and Western blotting data in uveal
melanoma cell lines and primary uveal melanomas</span></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Immunohistochemistry
</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Immunofluorescence results of
total and phospho-ERK1/2 on a panel of 19 fresh frozen uveal melanoma sections
are listed in </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl2/"
target=true><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Table
2 (B)</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>.
In seven of the 19 primary tumours, less than 5% of the tumour cells stained
positively for ERK1/2 and nine tumours for phosphorylated ERK1/2. Despite the
lack of mutations in the <i>RAS</i> and <i>BRAF</i> genes in this set of uveal
melanomas, it is noteworthy that we observed phosphorylated (active) ERK1/2
expression in 10 of 19 tumours. There was no significant association between
ERK1/2 activation and tumour location or cell type. The scoring system for each
antibody cannot be compared between antibodies since the antibodies recognise
different epitopes and with different affinities; therefore, the staining
intensity on Western or by immunohistochemistry is relative only to the other
samples for the particular antibody used.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/"
title="Go to other sections in this page"><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>Go to:</span></a></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>DISCUSSION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>In the uveal
melanoma cell lines and primary uveal melanomas analysed in our study, only
cell line Ocm 1 carried a mutation in <i>BRAF</i> (V599E), thus confirming the documentation of a mutation in
this cell line by Calipel
<i>et al</i> (2003) and Kilic <i>et al</i> (2004).</span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>
Similarly, our observation of a complete lack of <i>BRAF</i> mutations in
primary uveal tumours mirrors the findings of several recent reports (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib4"><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cohen <i>et al</i>,
2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib7"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cruz <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib12"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Edmunds <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib29"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Rimoldi <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib42"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Weber <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib17"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Kilic <i>et
al</i>, 2004</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl3/"
target=true><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Table
3</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>
contains a summary of published reports on <i>RAS</i> and <i>BRAF</i>
mutations, as well as studies on other members of the MAPK pathway, in uveal
melanomas. Including the results of our study, to date not a single <i>BRAF</i>
mutation has been found in a total of 276 primary or secondary uveal melanoma
samples (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl3/"
target=true><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Table
3</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).
<span style='background:yellow'>It is somewhat surprising therefore that three out of three uveal melanoma cell
lines studied by Calipel <i>et al</i>
(2003)
carried the V599E mutation in <i>BRAF</i>,
especially since only one out of 11 cell lines in the panel we analysed was
found to have this mutation.</span> Taken together, these data suggest that
while a <i>BRAF</i> mutation is not required for uveal melanoma development <i>in
vivo</i>, such mutations confer a cellular growth advantage and are hence
selected if they occur in cell lines cultured <i>in vitro</i>.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl3/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=204 height=140 id="Picture 1"
src="PMC2361800%20table%202_files/image005.png" alt="Table 3"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/table/tbl3/"
target=table><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Table
3</span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Summary
of published <i>RAS</i> and <i>BRAF</i> mutation studies in ocular melanoma</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>In our study,
none of the cell lines or primary tumours carried mutations in any of the three
<i>RAS</i> genes (N, H and K), a finding consistent with a previous report (Soparker
<i>et al</i>, 1993).</span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'> These
mutation data are in stark contrast to that for cutaneous melanoma, and would
appear to suggest that the MAPK pathway is unlikely to play a significant role
in uveal melanoma development. However, on the contrary, by Western blot
analysis and immunohistochemistry, we have found substantial evidence for
activation of the MAPK pathway, in the absence of serum, in the majority of
uveal melanoma samples  both cell lines and primary uveal melanoma specimens.
This frequent MAPK pathway activation in uveal melanoma, independent of <i>RAS</i>
and <i>BRAF</i> mutations, has also been reported recently by others (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib29"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Rimoldi <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib42"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Weber <i>et
al</i>, 2003</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;),
but the mechanism is unknown. Recently, an interaction has been found between
the MAPK and the PTEN pathways, both frequently activated in parallel to
promote cutaneous melanoma development (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib38"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Tsao <i>et
al</i>, 2004</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>).
It is tempting to speculate that MAPK activation in uveal melanoma may arise
via crosstalk with the PI3K/PTEN/AKT pathway, possibly as a consequence of
mutation of some of its components (other than PTEN, which is not mutated in
this tumour type). Thus, mutation analysis of the PI3K and AKT gene families in
uveal melanomas seems warranted. Interestingly, </span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib14"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Graells <i>et
al</i> (2004)</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>
demonstrated that the proangiogenic vascular endothelial growth factor (VEGF),
which is frequently highly expressed in uveal melanoma (</span><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib37"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Stitt <i>et
al</i>, 1998</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>;
</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#bib32"><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Sheidow <i>et
al</i>, 2000</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>),
could operate in cutaneous melanoma as a survival factor through increasing
MAPK and PI3K pathway activity. It is possible that MAPK activation is such a
crucial requirement for uveal melanoma development because it similarly
provides survival, and/or antiapoptotic signals, necessary for tumour cell
growth and maintenance.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Although many uveal melanoma
samples have been studied for <i>BRAF</i> and <i>NRAS</i> mutations, few have
been analysed for MAPK activation and there is the implicit assumption that
this pathway is not involved in uveal melanoma genesis. Our study is the only
study design providing mutation information on all RAS members and expression
data on a wide range of participants in the MAPK pathway. Our data thus support
the notion that activation of MAPK is indeed involved in the development of
uveal melanoma, but occurs via a different mechanism(s) to that in the majority
of cutaneous melanomas. This conclusion has significant ramifications for the
development of rational therapies to treat uveal melanoma as it implies that
general inhibitors of the pathway may still be effective even though the
tumours do not have mutations of <i>RAS</i> or <i>BRAF</i>.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/"
title="Go to other sections in this page"><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>Go to:</span></a></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>Acknowledgments</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>We thank Dr AD Singh for
generously providing a panel of fresh frozen primary uveal melanoma specimens,
Dr M Bernsen and P Rombout for the cutaneaous melanoma sections (Department of
Pathology, University Medical Centre Nijmegen) and Drs Ksander and Kan-Mitchell
for providing some of the cell lines. This work was supported by the National
Health and Medical Research Council of Australia, the Rotterdamse Vereniging Blindenbelangen'
and the Landelijke Stichting voor Blinden en Slechtzienden'. FvN is supported
by the Netherlands Organisation for Scientific Research and by the Dutch Cancer
Society. NG is a recipient of an Aspasia fellowship of the Netherlands Organisation
for Scientific Research.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/"
title="Go to other sections in this page"><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>Go to:</span></a></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase'>References</span></b></p>

</div>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Alsina J, Gorsk DH, Germino
     FJ, Shih W, Lu SE, Zhang ZG, Yang JM, Hait WN, Goydos JS. Detection of
     mutations in the mitogen-activated protein kinase pathway in human
     melanoma. Clin Cancer Res. 2003;9:64196425. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/14695143" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Brose MS, Volpe P, Feldman
     M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A,
     Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA,
     Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung
     cancer and melanoma. Cancer Res. 2002;62:69977000. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12460918" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Calipel A, Lefevre G,
     Pouponnot C, Mouriaux F, Eychene A, Mascarelli F. Mutation of B-Raf in
     human choroidal melanoma cells mediates cell proliferation and
     transformation through the MEK/ERK pathway J Biol Chem
     20032784240942418.42418doi:10.1074/jbcM308709200 [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12917419" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1074%2FjbcM308709200" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross
     Ref</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Cohen Y, Goldenberg-Cohen N,
     Parrella P, Chowers I, Merbs SL, Pe'er J, Sidransky D. Lack of BRAF
     mutation in primary uveal melanoma Invest Ophthalmol Vis Sci
     20034428762878.2878doi:10.1167/iovs.02-1329 [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12824225" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1167%2Fiovs.02-1329" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross
     Ref</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Cohen Y, Rosenbaum E, Begum
     S, Goldenberg D, Esche C, Lavie O, Sidransky D, Westra WH. Exon 15 BRAF
     mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin
     Cancer Res. 2004;10:34443447. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15161700" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Cohen C, Zavala-Pompa A,
     Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B,
     Macaron N, Arbister JL. Mitogen-activated protein kinase activation is an
     early event in melanoma progression. Clin Cancer Res. 2002;8:37283733. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12473582" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Cruz F, III, Rubin BP,
     Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless
     CL. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res.
     2003;63 18:57615766. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/14522897" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Davies H, Bignell GR, Cox C,
     Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ,
     Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R,
     Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S,
     Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J,
     Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ,
     Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY,
     Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall
     CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in
     human cancer Nature 2002417949954.954doi:10.1038/nature00766 [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12068308" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1038%2Fnature00766" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross
     Ref</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>de Waard-Siebinga I, Blom
     DJ, Griffioen M, Schrier PI, Hoogendoorn E, Beverstock G, Danen EH, Jager
     MJ. Establishment and characterization of an uveal-melanoma cell line. Int
     J Cancer. 1995;62:155161. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/7622289" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Diener-West M, Hawkins BS,
     Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma.
     II. A meta-analysis of 5-year mortality rates following enucleation, 1966
     through 1988. Arch Ophthalmol. 1992;110:245250. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/1531290" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Dong J, Phelps RG, Qiao R,
     Yao S, Benard O, Ronai Z, Aaronson SA. BRAF oncogenic mutations correlate
     with progression rather than initiation of human melanoma. Cancer Res.
     2003;63 14:38833885. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12873977" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Edmunds SC, Cree IA, Di
     Nicolantonio F, Hungerford JL, Hurren JS, Kelsell DP. Absence of BRAF gene
     mutations in uveal melanomas in contrast to cutaneous melanomas Br J
     Cancer 20038814031405.1405doi:10.1038/sj.bjc.6600919 [</span><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741050/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMC free
     article</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]
     [</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/12778069"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1038%2Fsj.bjc.6600919" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross
     Ref</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Gorden A, Osman I, Gai W, He
     D, Huang W, Davidson A, Houghton AN, Busam K, Polsky D. Analysis of BRAF
     and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 2003;63
     14:39553957. [</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/12873990"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Graells J, Vinyals A,
     Figueras A, Llorens A, Moreno A, Marcoval J, Gonzalez FJ, Fabra A. Overproduction
     of VEGF concomitantly expressed with its receptors promotes growth and
     survival of melanoma cells through MAPK and PI3K signaling. J Invest
     Dermatol. 2004;123:11511161. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15610528" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Guldberg P, thor Straten P,
     Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN
     gene by deletion or mutation is a frequent event in malignant melanoma.
     Cancer Res. 1997;57:36603663. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/9288767" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Kan-Mitchell J, Mitchell MS,
     Rao N, Liggett PE. Characterization of uveal melanoma cell lines that grow
     as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci. 1989;30:829834.
     [</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/2722439"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Kilic E, Bruggenwirth HT,
     Verbiest MM, Zwarthoff EC, Mooy NM, Luyten GP, De Klein A. The RAS-BRAF
     kinase pathway is not involved in uveal melanoma. Melanoma Res.
     2004;14:203205. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15179189" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Kumar R, Angelini S, Czene
     K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, Hemminki K. BRAF mutations in
     metastatic melanoma: a possible association with clinical outcome. Clin
     Cancer Res. 2003a;9:33623368. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12960123" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Kumar R, Angelini S,
     Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary
     melanomas: an inverse association with allelic loss on chromosome 9
     Oncogene 2003b2292179224.9224doi:10.1038/sj.onc.1206909 [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/14681681" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1038%2Fsj.onc.1206909" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross
     Ref</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Luyten GP, Naus NC, Mooy CM,
     Hagemeijer A, Kan-Mitchell J, van Drunen E, Vuzevski V, de Jong PT, Luider
     TM. Establishment and characterization of primary and metastatic uveal
     melanoma cell lines Int J Cancer
     199666380387.387doi:10.1002/(sici)1097-0215 [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/8621261" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1002%2F(sici)1097-0215" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross
     Ref</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Maldonado JL, Fridlyand J,
     Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D,
     Bastian BC. Determinants of BRAF mutations in primary melanomas. J Natl
     Cancer Inst. 2003;95:18781890. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/14679157" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Miller SA, Dykes DD, Polesky
     HF. A simple salting out procedure for extracting DNA from human nucleated
     cells. Nucl Acids Res. 1988;16:1215. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC334765/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMC free
     article</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]
     [</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/3344216"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Mooy CM, de Jong PT.
     Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol.
     1996;41:215228. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/8970236" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Mooy CM, Van der Helm MJ,
     Van der Kwast TH, De Jong PT, Ruiter DJ, Zwarthoff EC. No N-ras mutations
     in human uveal melanoma: the role of ultraviolet light revisited. Br J
     Cancer. 1991;64:411413. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977515/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMC free
     article</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]
     [</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/1892776"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Naus NC, Zuidervaart W,
     Rayman N, Slater R, van Drunen E, Ksander B, Luyten GP, Klein A. Mutation
     analysis of the PTEN gene in uveal melanoma cell lines. Int J Cancer.
     2000;87:151153. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/10861467" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Omholt K, Platz A, Kanter L,
     Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma
     pathogenesis and are preserved throughout tumor progression. Clin Cancer
     Res. 2003;9:64836488. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/14695152" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Pollock PM, Harper UL,
     Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U,
     Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward
     NK, Trent JM, Meltzer PS. High frequency of BRAF mutations in nevi Nat
     Genet 2003331920.20doi:10.1038/ng1054 [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12447372" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1038%2Fng1054" target="pmc_ext"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross Ref</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Reifenberger J, Knobbe CB,
     Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, Reifenberger G. Frequent
     alterations of Ras signaling pathway genes in sporadic malignant melanomas
     Int J Cancer 2004109377384.384doi:10.1002/ijc.11722 [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/14961576" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1002%2Fijc.11722" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross
     Ref</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Rimoldi D, Salvi S, Lienard
     D, Lejeune FJ, Speiser D, Zografos L, Cerottini JC. Lack of BRAF mutations
     in uveal melanoma. Cancer Res. 2003;63:57125715. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/14522889" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Satyamoorthy K, Li G,
     Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M.
     Constitutive mitogen-activated protein kinase activation in melanoma is
     mediated by both BRAF mutations and autocrine growth factor stimulation.
     Cancer Res. 2003;63:756759. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12591721" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Scott RJ, Vajdic CM,
     Armstrong BK, Ainsworth CJ, Meldrum CJ, Aitken JF, Kricker A. BRCA2
     mutations in a population-based series of patients with ocular melanoma
     Int J Cancer 2002102188191.191doi:10.1002/ijc.10693 [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12385017" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1002%2Fijc.10693" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross
     Ref</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Sheidow TG, Hooper PL,
     Crukley C, Young J, Heathcote JG. Expression of vascular endothelial
     growth factor in uveal melanoma and its correlation with metastasis. Br J
     Ophthalmol. 2000;84:750756. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1723542/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMC free
     article</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]
     [</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/10873988"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Shinozaki M, Fujimoto A,
     Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical
     relevance for primary cutaneous melanomas. Clin Cancer Res.
     2004;10:17531757. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15014028" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Sisley K, Rennie IG, Parsons
     MA, Jacques R, Hammond DW, Bell SM, Potter AM, Rees RC. Abnormalities of
     chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis
     Genes Chromosomes Cancer 1997192228.28doi:10.1002/(sici)1098-2264(199705)
     [</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/9135991"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1002%2F(sici)1098-2264(199705)" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross
     Ref</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Soparker CN, O'Brien JM,
     Albert DM. Investigation of the role of the ras protooncogene point
     mutation in human uveal melanomas. Invest Ophthalmol Vis Sci. 1993;34:22032209.
     [</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/8505202"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Stahl JM, Cheung M, Sharma
     A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor
     development in malignant melanoma. Cancer Res. 2003;63:28812890. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12782594" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Stitt AW, Simpson DA,
     Boocock C, Gardiner TA, Murphy GM, Archer DB. Expression of vascular
     endothelial growth factor (VEGF) and its receptors is regulated in eyes
     with intra-ocular tumours. J Pathol. 1998;186:306312. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/10211121" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Tsao H, Goel V, Wu H, Yang
     G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and
     PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004;122:337341.
     [</span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586668/"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMC
     free article</span></a><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif"'>] [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15009714" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Uribe P, Wistuba II,
     Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and
     malignant melanocytic lesions of the skin. Am J Dermatopathol.
     2003;25:365370. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/14501284" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>van der Velden PA,
     Metzelaar-Blok JA, Bergman W, Hurks HMH, Frants RR, Gruis NA, Jager MJ.
     Promoter hypermethylation: a common cause of reduced p16(INK4a) expression
     in uveal melanoma. Cancer Res. 2001;61:53035306. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pubmed/11431374" target="pmc_ext"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>van Elsas A, Zerp SF, van
     der Flier S, Kruse KM, Aarnoudse C, Hayward NK, Ruiter DJ, Schrier PI.
     Relevance of ultraviolet-induced N-ras oncogene point mutations in
     development of primary human cutaneous melanoma. Am J Pathol.
     1996;149:883893. [</span><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1865150/"><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMC free
     article</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]
     [</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/8780392"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Weber A, Hengge UR, Urbanik
     D, Markwart A, Mirmohammadsaegh, Reichel MB, Wittekind C, Wiedemann P,
     Tannapfel A. Absence of mutations of the BRAF gene and constitutive
     activation of extracellulr-regulated kinase in malignant melanomas of the
     uvea Lab Invest 20038317711776.1776doi:10.1097/01.LAB.0000101732.89463.29
     [</span><a href="http://www.ncbi.nlm.nih.gov/pubmed/14691295"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PubMed</span></a><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>] [</span><a
     href="http://dx.doi.org/10.1097%2F01.LAB.0000101732.89463.29"
     target="pmc_ext"><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Cross
     Ref</span></a><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>]</span></li>
 <li class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
     12.0pt;font-family:"Times New Roman","serif"'>Yazdi AS, Palmedo G, Flaig
     MJ, Kutzner H, Sander CA. SP-11 different frequencies of a BRAF point
     mutation in melanocytic skin lesions. Pigment Cell Res. 2003;16:580.</span></li>
</ul>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#__abstractid949447title"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
     display:none'>Abstract</span></a></li>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#__sec1title"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
     display:none'>MATERIALS AND METHODS</span></a></li>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#__sec6title"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
     display:none'>RESULTS</span></a></li>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#__sec10title"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
     display:none'>DISCUSSION</span></a></li>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#__ackid1005665title"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
     display:none'>Acknowledgments</span></a></li>
 <li class=MsoNormal style='line-height:normal'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361800/#__ref-listid1005677title"><span
     lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
     display:none'>References</span></a></li>
</ul>

<div class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal'><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal'><span lang=EN style='font-size:12.0pt;
font-family:"Arial","sans-serif"'>Articles from British Journal of Cancer are
provided here courtesy of <b>Cancer Research UK</b></span></p>

<p class=MsoNormal>&nbsp;</p>

</div>

</body>

</html>
